| Document |
Document Title |
|
WO/2024/032597A1 |
A compound having a STING inhibitory effect or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for treating diseases related to abnormal STING expression. Specifically disclosed are compounds of...
|
|
WO/2024/023314A1 |
The invention relates to the novel compounds of formula (I) as well as ions, stereoisomers, tautomers, hydrates, solvates, pharmaceutically acceptable salts thereof, or mixtures of the same. The compounds of formula (I) are ligands that ...
|
|
WO/2022/241470A9 |
Disclosed herein are methods of molecular magnetic resonance (MR) imaging and positron emission tomography using extracellular probes that target extracellular allysine aldehyde and act as a noninvasive biomarker of fibrogenesis with hig...
|
|
WO/2023/220836A1 |
The present disclosure relates generally to new bifunctional linchpins that react selectively with cysteine residues to invoke cyclization while concurrently introducing a radiometal chelation ligand or silicon-based fluoride acceptor (S...
|
|
WO/2023/277594A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2022/204065A1 |
The present application describes novel Fe(III) macrocyclic complexes that have hydroxy pendants with a third anionic ancillary group for improved MR imaging in vivo. The complexes have the following general structure:(I) or (II) where h...
|
|
WO/2022/194261A1 |
A compound as represented by formula (I), a stereoisomer and tautomer thereof or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating pain and a spinal cord injury.
|
|
WO/2022/194298A1 |
Cyclic 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid chelators and metal complexes comprising the same useful as positron emission tomography imaging agents, magnetic resonance imaging contrast agents, and computed tomography imaging ...
|
|
WO/2022/162014A1 |
The present invention concerns aza-cryptophanes, processes for preparation thereof, and their uses, in particular as in vivo diagnostic tools when complexing a hyperpolarized noble element, or in nanoemulsions.
|
|
WO/2022/155037A1 |
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1‑R8, X, Y, Z, X', Y'...
|
|
WO/2022/122177A1 |
The present invention concerns a granule comprising Mn(ll) oxalate, a protonated salt of a cyclic triamine, a polysaccharide absorbent and a coating agent. In another embodiment the invention concerns a granule comprising a polysaccharid...
|
|
WO/2022/061193A1 |
Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in ...
|
|
WO/2022/037650A1 |
Provided herein are bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts, which are as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. Also provided are methods for preparing Compounds A and B o...
|
|
WO/2021/233851A1 |
The invention relates to a compound of formula (I) wherein R1-R2 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/226161A1 |
An improved process for preparing verdiperstat is disclosed. The process includes the steps of reacting a compound having formula or a salt thereof, wherein R is the same or different and is each independently a C1-C5 alkyl with 3-(dimet...
|
|
WO/2021/170840A1 |
The present invention relates to a method of degrading biofilm by contacting it with an aqueous mixture comprising a peroxide compound and a manganese complex, wherein the aqueous mixture comprises a macrocylic ligand. The invention also...
|
|
WO/2021/145099A1 |
The objective of the present invention is to synthesize a zirconium complex by making even a low concentration of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) react with radioactive zirconium at a high reaction rate. A...
|
|
WO/2020/206503A9 |
The invention relates to compounds according to Formula (I) wherein A is –As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, -CH2NH, -NHCOCH3, -NHCOCH2X or NO, an...
|
|
WO/2021/043260A1 |
A pyrimidine compound, relating more specifically to a pyrimidine compound and a preparation method therefor, and a use thereof in the preparation of a drug. Provided is a compound represented by formula (I), or a tautomer, stereoisomer,...
|
|
WO/2021/019983A1 |
The purpose of the present invention is to react radioactive zirconium at a high reaction rate to synthesize a zirconium complex even using low-concentration DOTA or NOTA. A mixed solution, obtained by finally mixing zirconium dissolved ...
|
|
WO/2020/210909A1 |
This application relates to compounds of Formula I. R1a, R1b and R1c is –CO2H, –SO2H, –SO3H, –SO4H, –PO2H, –PO3H or –PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g.–O–, –S–, -S(O)-, S(O)2-, –NHC(O)–, ...
|
|
WO/2020/156106A1 |
Heterocyclic aryl formamides or a salt thereof, a preparation method, a weeding composition, and an application. The structural formula of the heterocyclic aryl formamide compound or the salt thereof is as shown in formula I, and the com...
|
|
WO/2020/150417A2 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/102820A1 |
Macrocyclic complexes and macrocyclic compounds. The macrocyclic complexes or macrocyclic compounds have a TACN moiety with one or more amine group(s) or a O- or S- substituted TACN moiety. The macrocyclic complexes have a high-spin Fe(I...
|
|
WO/2020/011228A1 |
Antibiotic compounds having both antibiotic and aggregation-induced emission (AIE) characteristics. The compounds comprise an azole antibiotic unit, for example naphthalimide triazole (NT), and an AIE unit, for example triphenylethylene ...
|
|
WO/2020/008204A1 |
The present invention relates to an oxidatively curable coating formulation comprising an oxidatively curable alkyd-based resin and unsymmetrically substituted 1,4,7- triazacyclononane-based chelant, which chelant may optionally be compl...
|
|
WO/2019/178510A1 |
Provided herein are triazacyclododecansulfonamide ("TCD")-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, p...
|
|
WO/2019/118313A1 |
Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: "Z" and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a re...
|
|
WO/2018/213853A1 |
Provided are macrocyclic compounds and compounds with two or more macrocyclic groups, iron coordinated macrocyclic compounds, and iron coordinated compounds with two or more macrocyclic groups. The iron is high-spin iron(III). The iron c...
|
|
WO/2018/202535A1 |
Substituted benzoyl amides and their use as herbicides. The invention relates to benzoyl amides of general formula (I) as herbicides. In formula (I) X, R and Ra represent radicals such as alkyl, cycloalkyl and halogen. Q is a five-member...
|
|
WO/2018/175418A1 |
16-membered macrolide compounds inhibit growth of various microbial species and have utility in the treatment of systemic or topical microbial infections, including methicillin-resistant strains (Formula I).
|
|
WO/2017/118174A1 |
The present invention discloses an organic functional compound for preparing an organic electronic device and an application thereof. The organic functional compound has a general formula (I). The organic functional compound comprises an...
|
|
WO/2017/055885A1 |
The invention relates to processes for the production of compounds of the general formula (I): wherein R1 is hydrogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, or phenyl group; and R2 is, independently of R1, a l...
|
|
WO/2016/153054A1 |
Provided are an efficient method for producing a nitrogen-containing compound or salt thereof to be used in the production of a treatment agent for diseases involving an integrin. Also provided is a production intermediate of the same. A...
|
|
WO/2014/201073A9 |
The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.
|
|
WO/2015/100609A1 |
Provided are new biphenyl derivatives of formula (Ia). These compounds act as aromatase and sulfatase inhibitors. They are particularly useful for treating pathological conditions or diseases in which aromatase and sulfatase are involved...
|
|
WO/2015/046916A1 |
The present invention relates to a specific combination of dopant compounds and host compounds. By using a combination of the dopant and host compounds according to the present invention, an organic electroluminescent device has improved...
|
|
WO/2014/177689A1 |
The present invention relates to a method of labelling biological molecules with 18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorpora...
|
|
WO/2014/157207A1 |
Provided is a room-temperature phosphorescent material which is responsive to external stimuli. A luminescent metal complex responsive to external stimuli according to the present invention is represented by general formula (I) (wherein ...
|
|
WO/2014/111639A1 |
The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a...
|
|
WO/2014/111661A1 |
The invention relates to complexing agents of formula (I) where A, chrom1, chrom2 and chrom3 are such as defined in the description. The invention also relates to lanthanide complexes resulting from said complexing agents.
|
|
WO/2014/079953A1 |
The present invention relates to a compound with formula (V'). The invention also relates to the synthesis method for compound (V') and its use for the preparation of 1,4,7-triazacyclononane (tacn) and N- and/or C-functionalized derivati...
|
|
WO/2014/040709A1 |
The present invention relates to a compound of formula (1) wherein X1 represents O or NR6, X2 represents O or NR6, X3 represents O or NR1, R1 represents H or C1 to C3 alkyl, R2 represents H, or a linear or branched C1 - C8 alkyl optional...
|
|
WO/2013/116682A1 |
The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of ...
|
|
WO/2013/090454A2 |
The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of ...
|
|
WO/2013/086396A1 |
Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation me...
|
|
WO/2013/065725A1 |
The present invention relates to a phthalamide derivative represented by general formula (I) or a salt thereof. [In the formula, X1 represents a halogen atom or the like; X2 represents a halogen atom or the like; m represents 0, 1, 2 or ...
|
|
WO/2012/175666A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, are useful as a pesticides and herbicides.
|
|
WO/2011/100838A9 |
Compounds of formula (I) wherein m, R1, R2, R3, X and Y are defined herein, are useful as inhibitors of HIV replication.
|
|
WO/2012/158707A1 |
Presently disclosed are methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist.
|
